宏光半導體(06908.HK)授出合共754萬股獎勵股份
格隆匯1月31日丨宏光半導體(06908.HK)公吿,於2024年1月31日,公司董事會根據股東於2023年12月29日採納的公司股份獎勵計劃,向合資格參與者授出合共754萬股公司股本中每股面值0.01港元的普通股(獎勵股份)的獎勵。
授出獎勵的目的為獎勵承授人過去所作出的貢獻及挽留彼等為集團的未來增長作出貢獻,並共享集團的未來增長。董事會認為,授出獎勵透過股份所有權、就股份派付的股息及其他分派及╱或股份的價值增長,使承授人的利益與集團利益一致,鼓勵承授人為集團的長期增長及利潤作出貢獻,此舉與股份獎勵計劃的目的相一致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.